Risk Management Guidance Suggests Using Claims Data To Evaluate Safety Signals
This article was originally published in The Pink Sheet Daily
Executive Summary
Three FDA risk management final guidances recommend that sponsors collect a wide range of safety data during both the clinical trial and postmarketing periods of drug development. The agency suggests that sponsors hold discussions with FDA before settling on drug study designs or postmarketing activities.
You may also be interested in...
RiskMAP Guidance Includes Plans For A Website
FDA is planning to develop a Risk Minimization Action Plan website, an agency risk management guidance states
RiskMAP Guidance Includes Plans For A Website
FDA is planning to develop a Risk Minimization Action Plan website, an agency risk management guidance states
FDA Drug Safety Review Will Consider Pros And Cons Of Separate Safety Agency
The agency is in discussions with the Institute of Medicine to initiate a study on the effectiveness of the drug safety system, particularly in the post-marketing phase. The IoM study is the centerpiece of an FDA drug safety initiative, announced Nov. 5, that packages together ongoing projects.